hit counter

Alzheimer’s PET Imaging Now Gates Anti-Amyloid Therapy Eligibility

MHD featured image for Alzheimer's PET imaging and anti-amyloid therapy eligibility.

A 2026 review in the Japanese Journal of Radiology argued that amyloid PET has moved from an optional Alzheimer’s disease biomarker to a practical eligibility gate for anti-amyloid antibody therapy, while tau PET and FDG-PET answer different questions in the same clinical workflow.1 The key shift is not that every memory complaint needs PET; it …

Read more

Plasma p-tau217 Blood Test Predicts Alzheimer’s Risk 1.5x Stronger in APOE-e4

Photoreal illustration representing a blood biomarker test for Alzheimer's disease with imagery of blood vials, neurons, and APOE genetic motifs.

Until recently, Alzheimer’s pathology could only be confirmed in living patients via PET imaging or lumbar puncture. Plasma p-tau217 changed that calculus — but how to interpret a positive result depends substantially on APOE genotype.1 Research Highlights Plasma p-tau217 is a blood biomarker that rises years before Alzheimer’s symptoms. The 2024 Alzheimer’s Association revised criteria …

Read more